Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer
NCT ID: NCT00104130
Last Updated: 2008-09-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
53 participants
INTERVENTIONAL
2004-12-31
2005-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer
NCT04100018
Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer
NCT00003183
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
NCT00744497
A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer
NCT00134706
Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer
NCT00116142
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
KOS-862
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Metastatic disease.
* One previous treatment including docetaxel (Taxotere).
* At least 3 weeks since last surgery/radiation/chemotherapy
* ECOG Performance Status of 0, 1 or 2
Exclusion Criteria
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kaiser Permanente Medical Center
Vallejo, California, United States
Georgia Cancer Specialists
Tucker, Georgia, United States
University of Maryland Medical System
Baltimore, Maryland, United States
Washington University School of Medicine
St Louis, Missouri, United States
The Cleveland Clinic Foundation
Cleveland, Ohio, United States
Kaiser Permanente NW Oncology Clinic
Portland, Oregon, United States
Oregon Health & Science University
Portland, Oregon, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
University of Washington
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KOS-202/NO18401
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.